Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Total Liabilities
Everything the company owes to creditors and other parties.
Aktis Oncology, Inc.NASDAQ: AKTS
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities of $70.69M in Q1 FY2026
Q1 FY2026 total liabilities was $70.69M. Over 3 fiscal years it compounded at +37.7% a year.
Context
- Total liabilities amounted to 12.3% of total assets at the end of Q1 FY2026.
- Total liabilities increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 411.03M USD
- Year-over-year change
- -0.7%
- 3-year CAGR
- +37.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 411.03M | -0.7% |
| FY2024 | 2024-12-31 | 413.98M | +145.5% |
| FY2023 | 2023-12-31 | 168.66M | +7.1% |
| FY2022 | 2022-12-31 | 157.55M | — |
Total Liabilities vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 total liabilities of $70.69M is the 4th highest of the 6 companies compared; the peer median is $98.08M.
- Total liabilities amounts to 12.3% of total assets for AKTS, versus a peer median of 22.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $678.42M | +4.4% | +54.0% | 63.3% | |
| Mar 2026 | $196.68M | +35.2% | +10.9% | 90.3% | |
| Mar 2026 | $98.08M | -31.7% | -8.4% | 15.0% | |
| Mar 2026 | $70.69M | — | +37.7% | 12.3% | |
| Sep 2026 | $51.22M | +44.5% | +87.6% | 10.1% | |
| Mar 2026 | $30.43M | +10.9% | +4.7% | 22.1% | |
| Peer median (excluding AKTS) | $98.08M | +10.9% | +10.9% | 22.1% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.